Clinolipid + Intralipid

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Essential Fatty Acid Deficiency (EFAD)

Conditions

Essential Fatty Acid Deficiency (EFAD)

Trial Timeline

May 1, 2015 โ†’ Oct 1, 2016

About Clinolipid + Intralipid

Clinolipid + Intralipid is a approved stage product being developed by Baxter for Essential Fatty Acid Deficiency (EFAD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02476994. Target conditions include Essential Fatty Acid Deficiency (EFAD).

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT04555044ApprovedCompleted
NCT02476994ApprovedTerminated

Competing Products

20 competing products in Essential Fatty Acid Deficiency (EFAD)

See all competitors
ProductCompanyStageHype Score
L04RD1 + L04TD3CelltrionPhase 1
33
Azilsartan MedoxomilCelltrionPre-clinical
23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
77
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
85
Anagre Cap.YuhanApproved
85
Telmisartan/Amlodipine/Chlorthalidone(Truset)YuhanPre-clinical
23
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo + olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil/hydrochlorothiazide tablets + olmesartan medoxomil/hydrochlorothiazide tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + losartan + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
77
CS8635 20/5/12.5mg and placebo + Olmetecยฎ Plus 20/12.5mg and placeboDaiichi SankyoPhase 3
77
CS-3150 + olmesartan medoxomilDaiichi SankyoPre-clinical
23
olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo + Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + hydroclororthiazide + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipine + olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77
Olmesartan medoxomil + Atenolol + Hydrochlorothiazide + olmesartan medoxomil + atenololDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
CS-3150 + EplerenoneDaiichi SankyoPhase 3
77
olmesartan medoxomil + losartan potassiumDaiichi SankyoPhase 3
77
Olmesartan medoxomil 40 mg - Amlodipine 10 mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg + Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg + OLM 40mg-AML 10mg-Hydrochlorothiazide 25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
85
Olmesartan medoxomil + Losartan + Furosemide oral tabletsDaiichi SankyoPhase 3
77
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets + olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgDaiichi SankyoPhase 3
77
olmesartan medoxomil + amlodipineDaiichi SankyoPhase 3
77